Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia-reperfusion injury in mice

Kidney International

Volumn 85, Issue 4, 2014, Pages 824-832

  Wu, Huiling ^a,b   Steenstra, Renske ^b   De Boer, Elianne C S ^b   Zhao, Cathy Y ^b   Ma, Jin ^b   Van Der Stelt, Jorieke M ^b   Chadban, Steven J ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Acute kidney injury; Inflammation; Ischemia reperfusion

Indexed keywords

CREATININE; HIGH MOBILITY GROUP B1 PROTEIN; PROTECTIVE AGENT; RECOMBINANT HIGH MOBILITY GROUP BOX 1 PROTEIN; REGULATOR PROTEIN; SIGLEC G PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LECTIN; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT PROTEIN; SIGLECG PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; KIDNEY ISCHEMIA; KIDNEY TUBULE DAMAGE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; ACUTE KIDNEY INJURY; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECTS; DRUG SCREENING; FEEDBACK SYSTEM; ISCHEMIC PRECONDITIONING; KIDNEY; METABOLISM; PROCEDURES;

ACUTE KIDNEY INJURY; ANIMALS; APOPTOSIS; CHEMOKINES; DRUG EVALUATION, PRECLINICAL; FEEDBACK, PHYSIOLOGICAL; HMGB1 PROTEIN; ISCHEMIC PRECONDITIONING; KIDNEY; LECTINS; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; NF-KAPPA B; RECEPTORS, ANTIGEN, B-CELL; RECOMBINANT PROTEINS; REPERFUSION INJURY; TOLL-LIKE RECEPTOR 4;

EID: 84897954325     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.475     Document Type: Article

References (25)

1. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451-1462.
2. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol 2009; 130: 41-50.
3. Wu H, Chen G, Wyburn KR et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117: 2847-2859.
4. Leemans JC, Stokman G, Claessen N et al. Renal-Associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005; 115: 2894-2903.
5. Zhai Y, Shen XD, O'Connell R et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004; 173: 7115-7119.
6. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342.
7. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
8. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
9. Abraham E, Arcaroli J, Carmody A et al. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165: 2950-2954.
10. Tsung A, Sahai R, Tanaka H et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201: 1135-1143.
11. Andrassy M, Volz HC, Igwe JC et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008; 117: 3216-3226.
12. Wu H, Ma J, Wang P et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 2010; 21: 1878-1890.
13. Bonventre JV. Kidney ischemic preconditioning. Curr Opin Nephrol Hypertens 2002; 11: 43-48.
14. Klune JR, Billiar TR, Tsung A. HMGB1 preconditioning: Therapeutic application for a danger signal?. J Leukoc Biol 2008; 83: 558-563.
15. Izuishi K, Tsung A, Jeyabalan G et al. Cutting edge: High-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol 2006; 176: 7154-7158.
16. Aneja RK, Tsung A, Sjodin H et al. Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance. J Leukoc Biol 2008; 84: 1326-1334.
17. Dessing MC, Pulskens WP, Teske GJ et al. RAGE does not contribute to renal injury and damage upon ischemia/reperfusion-induced injury. J Innate Immun 2012; 4: 80-85.
18. Chen GY, Tang J, Zheng P et al. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009; 323: 1722-1725.
19. Hu X, Jiang H, Cui B et al. Preconditioning with high mobility group box 1 protein protects against myocardial ischemia-reperfusion injury. Int J Cardiol 2010; 145: 111-112.
20. McDonald S, Russ G, Campbell S et al. Kidney transplant rejection in Australia and New Zealand: Relationships between rejection and graft outcome. Am J Transplant 2007; 7: 1201-1208.
21. Lech M, Avila-Ferrufino A, Allam R et al. Resident dendritic cells prevent postischemic acute renal failure by help of single Ig IL-1 receptor-related protein. J Immunol 2009; 183: 4109-4118.
22. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296: 301-305.
23. Crocker PR, Varki A. Siglecs, sialic acids and innate immunity. Trends Immunol 2001; 22: 337-342.
24. Wu H, Noordmans GA, O'Brien MR et al. Absence of MyD88 signaling induces donor-specific kidney allograft tolerance. J Am Soc Nephrol 2012; 23: 1701-1716.
25. Goldstein DR, Tesar BM, Akira S et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111: 1571-1578.